← board
APLMW
distress 6/10 · elevated risk$0.02-13%today-39% from 52w high
Revenue
pre-revenue
Liquidity
$3M
Runway
0.3 yrs
Shares 1y
0%
Price & events
-39.2% over 6M
CatalystRating changeDilutionFinancingdashed = today
-12.7%
1D
+35.0%
1W
+13.7%
1M
+13.7%
3M
-39.2%
6M
-39.2%
1Y
—
2Y
—
5Y
-39.2%
All
Overview
- Market Cap
- $34.70K
- Volume
- 130
- 52 Week Range
- $0.01 – $0.03
- Total Shares
- 2.20M
- RVOL
- 0.01x
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 0
- No catalyst news yet.
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors
- none identified
Recent news
- 2026-07-01Apollomics Inc. Warrant 2023-01.04.28 on Apollomics Financial Disclosures & SEC Filings - TradingView
- 2026-06-25Apollomics Receives Nasdaq Deficiency Notice Regarding Minimum Market Value Requirement and Updates Rights for Vebreltinib (APL-101) in Asia - Sahm
- 2026-06-19Apollomics Inc (APLMW) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
- 2026-06-19Apollomics Inc (APLMW) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
- 2026-05-26Apollomics Inc. Warrant (APLMW) Stalls at $0.01: Micro-Cap Warrant Holds Steady Amid Minimal Trading Activity - ALMA Signal - lwvtexas.org
- 2026-04-29Is Apollomics (APLMW) dividend sustainable? (Smart Money Exits) 2026-04-29 - Factor Momentum - The Legal Advocate
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.